# GLB1L3

## Overview
GLB1L3 is a gene that encodes the protein galactosidase beta 1 like 3, which is part of the glycoside hydrolase family. This protein is involved in the hydrolysis of glycosidic bonds, a critical function in the metabolism of carbohydrates. While the specific biological roles of GLB1L3 are not fully understood, it has been implicated in various physiological and pathological processes, including glucose metabolism and neurological disorders. The gene's expression and potential interactions suggest it may play a role in complex biological pathways, although further research is necessary to elucidate its precise functions and mechanisms (Liu2022A; Li2021Overlapping).

## Structure


## Function


## Clinical Significance
The GLB1L3 gene has been implicated in several health conditions, although its exact clinical significance remains to be fully elucidated. It has been associated with prediabetes status change, suggesting a potential role in glucose metabolism. This association was identified through a genome-wide association study, which found significant links between GLB1L3 and prediabetes, although the biological mechanisms remain unclear (Liu2022A).

GLB1L3 is also involved in the genetic architecture of schizophrenia and amyotrophic lateral sclerosis (ALS). Studies have shown that GLB1L3 has overlapping gene expression profiles in tissues affected by these disorders, indicating a possible role in their pathogenesis. However, the specific clinical implications of these findings are not yet fully understood (Li2021Overlapping).

In the context of prostate cancer, GLB1L3 is part of a gene expression signature associated with Gleason Score, which is used to predict prostate cancer outcomes. While it is included in this signature, the direct clinical significance of GLB1L3 in prostate cancer is not detailed (Jhun2017Gene). Overall, further research is needed to clarify the clinical roles of GLB1L3 in these conditions.


## References


[1. (Jhun2017Gene) Min A. Jhun, Milan S. Geybels, Jonathan L. Wright, Suzanne Kolb, Craig April, Marina Bibikova, Elaine A. Ostrander, Jian-Bing Fan, Ziding Feng, and Janet L. Stanford. Gene expression signature of gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget, 8(26):43035â€“43047, April 2017. URL: http://dx.doi.org/10.18632/oncotarget.17428, doi:10.18632/oncotarget.17428. This article has 29 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.17428)

[2. (Liu2022A) Tingting Liu, Hongjin Li, Yvette P. Conley, Brian A. Primack, Jing Wang, Wen-Juo Lo, and Changwei Li. A genome-wide association study of prediabetes status change. Frontiers in Endocrinology, June 2022. URL: http://dx.doi.org/10.3389/fendo.2022.881633, doi:10.3389/fendo.2022.881633. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2022.881633)

[3. (Li2021Overlapping) Chunyu Li, Tianmi Yang, Ruwei Ou, and Huifang Shang. Overlapping genetic architecture between schizophrenia and neurodegenerative disorders. Frontiers in Cell and Developmental Biology, December 2021. URL: http://dx.doi.org/10.3389/fcell.2021.797072, doi:10.3389/fcell.2021.797072. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.797072)